Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

15-Year Follow-up of Protection and Immunity After Bivalent HPV Vaccination in Women (HPV Vaccine)

14 november 2026 bijgewerkt door: Jun Zhang, Xiamen University

A 15-Year Follow-up Study of Long-Term Protection and Immunopersistence of an Escherichia Coli-Produced Bivalent HPV-16/18 Vaccine in Healthy Women Aged 18-45 Years

This study aims to evaluate the long-term protection provided by a bivalent HPV vaccine produced in Escherichia coli against specific clinical endpoints related to HPV types 16 and 18 in women aged 18-45 years, as well as the persistence of antibodies specific to these two HPV types.

Studie Overzicht

Gedetailleerde beschrijving

This observational study is a long-term follow-up of participants in the phase III clinical trial of a bivalent HPV 16/18 vaccine produced in Escherichia coli (HPV-PRO-003, NCT01735006). Women aged 18-45 years at enrollment in the original trial were randomly assigned to receive either the HPV vaccine or a hepatitis E vaccine. The follow-up study will retain the original vaccine and control groups. No additional study intervention will be administered.

Through 15 years after the first dose, this study aims to evaluate the long-term protection provided by the bivalent HPV vaccine against specific clinical endpoints associated with HPV types 16 and/or 18 and to assess the persistence of antibodies specific to HPV types 16 and 18.

Studietype

Observationeel

Inschrijving (Geschat)

2000

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • Guangxi
      • Liuzhou, Guangxi, China, 545007
        • Liuzhou Center for Disease Control and Prevention
        • Contact:
    • Hebei
      • Fengning, Hebei, China, 068350
        • Fengning Hospital of Traditional Chinese Medicine
        • Contact:
    • Henan
      • Qingpingjie, Henan, China, 452370
        • Xinmi Maternal and Child Health Hospital
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Kind
  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Vrouw

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

The study population comprises women who received at least one dose of their assigned vaccine in the original phase III trial of the Escherichia coli-produced recombinant bivalent vaccine against human papillomavirus (HPV) types 16 and 18 (protocol HPV-PRO-003). To be eligible, women must not have received any HPV vaccine outside their original trial assignment since enrollment in that trial, including any subsequent catch-up doses given to control group participants. Participants retain their original group assignments (HPV vaccine group or hepatitis E vaccine control group).

Beschrijving

Inclusion Criteria:

  • The participant took part in the phase III trial of the Escherichia coli-produced recombinant bivalent vaccine against human papillomavirus (HPV) types 16 and 18 (protocol HPV-PRO-003) and received at least one dose of the vaccine assigned to her in that trial.
  • The participant has given informed consent and signed the consent form.
  • The participant is able to complete all study procedures as required by the protocol.

Exclusion Criteria:

  • Since enrollment in the original phase III trial, the participant has received any HPV vaccine other than the study vaccination assigned under the original trial protocol. This includes subsequent catch-up vaccination with the investigational vaccine among participants in the original control group, as well as receipt of any other licensed or unlicensed HPV vaccine.
  • The participant had an invasive malignancy of the cervix, vagina, or vulva before enrollment in this follow-up study, or an abnormality detected at screening is confirmed to be an invasive malignancy at one of these sites by histopathological examination of a colposcopy-directed biopsy specimen.
  • In the investigator's judgment, a medical, psychological, social, occupational, or other circumstance would interfere with the participant's ability to comply with the protocol or to provide written informed consent.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Observatiemodellen: COHORT
  • Tijdsperspectieven: PROSPECTIVE

Cohorten en interventies

Groep / Cohort
Interventie / Behandeling
Vaccine group

Women assigned to the vaccine group in the original phase III trial who received at least one dose of the bivalent HPV 16/18 vaccine. Since enrollment in the original trial, they must not have received any HPV vaccine other than the study vaccine administered as specified in that trial's protocol. Participants must also meet all other eligibility criteria for this follow-up study.

The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant

Control group

Women assigned to the control group in the original phase III trial who received at least one dose of control vaccine (hepatitis E vaccine). Since enrollment in the original trial, they must not have received any HPV vaccine other than vaccination specified in the original trial protocol. Participants must also meet all other eligibility criteria for this follow-up study.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
CIN2+, VIN2+, or VaIN2+ associated with HPV type 16 or 18 in the per-protocol population
Tijdsspanne: At months 156 and 180 after the first dose in the original trial

This endpoint includes grade 2 or worse cervical, vulvar, or vaginal intraepithelial neoplasia associated with either or both HPV types

At months 156 and 180 after the first dose in the original trial
6-month persistent infection with HPV type 16 or 18 in the per-protocol population
Tijdsspanne: At months 156 and 180 after the first dose in the original trial

Infection with the same HPV type must persist for at least 6 months

At months 156 and 180 after the first dose in the original trial

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
CIN1+, VIN1+, or VaIN1+ associated with HPV type 16 or 18
Tijdsspanne: At months 156 and 180 after the first dose in the original trial

This endpoint includes grade 1 or worse cervical, vulvar, or vaginal intraepithelial neoplasia associated with either or both HPV types

At months 156 and 180 after the first dose in the original trial
CIN2+ associated with HPV type 16 or 18
Tijdsspanne: At months 156 and 180 after the first dose in the original trial

This endpoint includes grade 2 or worse cervical intraepithelial neoplasia associated with either or both HPV types

At months 156 and 180 after the first dose in the original trial
VIN2+, or VaIN2+ associated with HPV type 16 or 18
Tijdsspanne: At months 156 and 180 after the first dose in the original trial

This endpoint includes grade 2 or worse vulvar, or vaginal intraepithelial neoplasia associated with either or both HPV types

At months 156 and 180 after the first dose in the original trial
HPV-16-specific infection and/or lesion endpoints
Tijdsspanne: At months 156 and 180 after the first dose in the original trial

6-month persistent infection and grade 2 or worse cervical intraepithelial

At months 156 and 180 after the first dose in the original trial
HPV-18-specific infection and/or lesion endpoints
Tijdsspanne: At months 156 and 180 after the first dose in the original trial

6-month persistent infection and grade 2 or worse cervical intraepithelial

At months 156 and 180 after the first dose in the original trial
Type-specific infection and/or lesion endpoints associated with other high-risk HPV types, including HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68
Tijdsspanne: At months 156 and 180 after the first dose in the original trial

6-month persistent infection and grade 2 or worse cervical intraepithelial

At months 156 and 180 after the first dose in the original trial
Type-specific seropositivity rates for HPV-16 and HPV-18 antibodies
Tijdsspanne: At months 156 and 180 after the first dose in the original trial

Percentage of participants seropositive for HPV-16 and HPV-18 antibodies

At months 156 and 180 after the first dose in the original trial
Type-specific HPV-16 and HPV-18 antibody levels
Tijdsspanne: At months 156 and 180 after the first dose in the original trial

Serum antibody titers against HPV-16 and HPV-18

At months 156 and 180 after the first dose in the original trial

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
incident HPV-16 and/or HPV-18 infection
Tijdsspanne: At months 156 and 180 after the first dose in the original trial

Newly detected HPV-16 and/or HPV-18 DNA positivity

At months 156 and 180 after the first dose in the original trial

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Studie stoel: Jun Zhang, Xiamen University
  • Hoofdonderzoeker: Ting Wu, Xiamen University

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Algemene publicaties

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 januari 2027

Primaire voltooiing (Geschat)

31 december 2029

Studie voltooiing (Geschat)

31 december 2029

Studieregistratiedata

Eerst ingediend

14 november 2026

Eerst ingediend dat voldeed aan de QC-criteria

14 november 2026

Eerst geplaatst (Werkelijk)

19 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

19 november 2026

Laatste update ingediend die voldeed aan QC-criteria

14 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

ONBESLIST

Beschrijving IPD-plan

Proposals should be sent to the Principal Investigator. Proposals will be reviewed and approved by the study team.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren